With FY 2025 soon drawing to a close, it is an ideal time to review portfolios and position for the year ahead.
Despite macro uncertainty and geopolitical concerns, some ASX 200 shares continue to deliver resilient earnings growth and have strong balance sheets and long-term tailwinds.
As a result, it is no wonder why analysts are tipping them as buys as we head into FY 2026. Let's see what is being recommended:
ResMed could be an ASX 200 share to buy for the new financial year. It is a medical device company with a focus on sleep disorder treatments.
It appears well-positioned for growth over the long term thanks to the sticky nature of CPAP usage for sleep apnoea and the growing awareness and diagnosis of sleep-related conditions. The latter is being supported (not hindered) by the rise of weight loss wonder drugs like Ozempic and technology like the Apple Watch.
And with a total addressable market (TAM) estimated to be over 1 billion for sleep apnoea, ResMed arguably has decades of growth ahead of it. It is partly for this reason that Macquarie has an outperform rating and $48.00 price target on its shares.
Another ASX 200 share for investors to consider buying is Pro Medicus.
It is a health imaging technology company that has been growing at a rapid rate for a number of years. This has been driven by Pro Medicus winning significant contracts from some of the biggest names in healthcare in the United States.
And with demand for advanced radiology platforms only expected to rise, and its Visage product suite the clear market leader, Pro Medicus has significant room to grow—both in the US and internationally.
And while its valuation remains rich, the company's proven ability to scale profitably and reinvest in innovation makes it a premium-quality tech healthcare stock worth paying up for. The team at Morgan Stanley certainly believes this is the case. The broker currently has an overweight rating and $310.00 price target on its shares.
Finally, TechnologyOne could be an ASX 200 share to buy for FY 2026. This enterprise software provider has been a standout performer for years—and that's unlikely to change in FY 2026.
It is successfully transitioning customers to its cloud SaaS platform, which offers predictable, high-margin recurring revenue. Government, education, and utility sectors make up the bulk of its client base, providing defensive earnings even during economic slowdowns.
Management certainly is confident in its outlook. It achieved its annual recurring revenue (ARR) target of $500 million 18 months ahead of schedule and is now aiming to grow it to $1 billion by 2030.
UBS is very positive on its outlook. So much so, it recently put a buy rating and $42.20 price target on its shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.